Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?

详细信息    查看全文

• 作者：Xuguang Chen (1)
  Jennifer R. Eads (2)
  John B. Ammori (3)
  Aryavarta M. Kumar (4)
  Tithi Biswas (4)
  Jennifer A. Dorth (4)
  
  1. School of Medicine ; Case Western Reserve University ; Cleveland ; OH ; USA
  2. Department of Internal Medicine ; Division of Hematology and Oncology ; University Hospitals Seidman Cancer Center ; Case Comprehensive Cancer Center ; Case Western Reserve University ; Cleveland ; OH ; USA
  3. Department of Surgery ; Division of Surgical Oncology ; University Hospitals Seidman Cancer Center ; Case Comprehensive Cancer Center ; Case Western Reserve University ; Cleveland ; OH ; USA
  4. Department of Radiation Oncology ; University Hospitals Seidman Cancer Center ; Case Comprehensive Cancer Center ; Case Western Reserve University ; Cleveland ; OH ; USA
  
• 关键词：Gastric cancer ; Adjuvant therapy ; Perioperative therapy ; Chemotherapy ; Chemoradiotherapy
• 刊名：Current Oncology Reports
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：17
• 期：4
• 全文大小：207 KB
• 参考文献：1. Martel, C, Forman, D, Plummer, M (2013) Gastric cancer: epidemiology and risk factors. Gastroenterol Clin N Am 42: pp. 219-40 3.01.003" target="_blank" title="It opens in new window">CrossRef
  2. Washington, K (2010) 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17: pp. 3077-9 34-010-1362-z" target="_blank" title="It opens in new window">CrossRef
  3. Ajani, JA, Bentrem, DJ, Besh, S (2013) Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 11: pp. 531-46
  4. Songun, I, Putter, H, Kranenbarg, EM (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11: pp. 439-49 CrossRef
  5. Hartgrink, HH, Velde, CJ, Putter, H (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22: pp. 2069-77 CrossRef
  6. Macdonald, JS, Smalley, SR, Benedetti, J (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: pp. 725-30 CrossRef
  7. Cunningham, D, Allum, WH, Stenning, SP (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: pp. 11-20 31" target="_blank" title="It opens in new window">CrossRef
  8. Raigani, S, Hardacre, JM, Kim, J, Ammori, JB (2014) Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol 21: pp. 569-74 34-013-3314-x" target="_blank" title="It opens in new window">CrossRef
  9. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715鈥?1. / The ACCORD 07 study demonstrated a benefit of perioperative chemotherapy on the rate of curative resection and five-year overall survival for gastric cancer.
  10. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo (radio) therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:Cd008107. / This Cochrane Review from 2013 demonstrated that perioperative chemotherapy is associated with a 19 % relative increase in 5-year overall survival (HR 0.81, 95 % CI 0.73-0.89), which translates to an absolute increase of 9 % in survival.
  11. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315鈥?1. / The CLASSIC trial (Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer) randomized patients to gastrectomy with D2 LND with or without adjuvant XELOX chemotherapy.
  12. Sakuramoto, S, Sasako, M, Yamaguchi, T (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: pp. 1810-20 CrossRef
  13. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327鈥?3. / After 10 years of follow up, there was a benefit in overall survival associated with adjuvant CRT (HR 1.32, 95 % CI 1.10-1.60, p = 0.0046).
  14. Lee J, Lim Do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268鈥?3. / The ARTIST trial found that there was no difference in disease-free survival between patients who received adjuvant chemotherapy versus chemoradiation.聽 However, an unplanned subgroup analysis demonstrated that CRT improved relative disease-free survival by 32 % among 300 patients with positive lymph node involvement (HR 0.68, 95 % CI 0.47-0.99, p = 0.047).聽
  15. Hartgrink, HH, Velde, CJ, Putter, H (2004) Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 30: pp. 643-9 3" target="_blank" title="It opens in new window">CrossRef
  16. Schuhmacher, C, Gretschel, S, Lordick, F (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol 28: pp. 5210-8 CrossRef
  17. Li, W, Qin, J, Sun, YH, Liu, TS (2010) Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 16: pp. 5621-8 3748/wjg.v16.i44.5621" target="_blank" title="It opens in new window">CrossRef
  18. Liao, Y, Yang, ZL, Peng, JS (2013) Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol 28: pp. 777-82 CrossRef
  19. Fujitani, K (2013) Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 30: pp. 119-29 350877" target="_blank" title="It opens in new window">CrossRef
  20. Noh, SH, Park, SR, Yang, HK (2013) Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial. Ann Oncol 24: pp. iv14 3/annonc/mdt201.7" target="_blank" title="It opens in new window">CrossRef
  21. Sasako, M, Sakuramoto, S, Katai, H (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29: pp. 4387-93 36.5908" target="_blank" title="It opens in new window">CrossRef
  22. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14: 113鈥?23.
  23. Lee, JH, Kim, JG, Jung, HK (2014) Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer 14: pp. 87-104 30/jgc.2014.14.2.87" target="_blank" title="It opens in new window">CrossRef
  24. Tsuburaya, A, Yoshida, K, Kobayashi, M (2014) Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 15: pp. 886-93 CrossRef
  25. Kang, YK, Chang, HM, Yook, JH (2013) Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer 108: pp. 1245-51 38/bjc.2013.86" target="_blank" title="It opens in new window">CrossRef
  26. Bajetta, E, Floriani, I, Bartolomeo, M (2014) Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 25: pp. 1373-8 3/annonc/mdu146" target="_blank" title="It opens in new window">CrossRef
  27. Paoletti, X, Oba, K, Burzykowski, T (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: pp. 1729-37 34" target="_blank" title="It opens in new window">CrossRef
  28. Diaz-Nieto, R, Orti-Rodriguez, R, Winslet, M (2013) Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev 9: pp. CD008415
  29. Markar, SR, Karthikesalingam, A, Jackson, D, Hanna, GB (2013) Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol 20: pp. 2328-38 34-012-2862-9" target="_blank" title="It opens in new window">CrossRef
  30. Biffi, R, Fazio, N, Luca, F (2010) Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 16: pp. 868-74
  31. Menges, M, Schmidt, C, Lindemann, W (2003) Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol 129: pp. 423-9 32-003-0467-1" target="_blank" title="It opens in new window">CrossRef
  32. Newman, E, Marcus, SG, Potmesil, M (2002) Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg 6: pp. 212-23 3" target="_blank" title="It opens in new window">CrossRef
  33. Tepper, JE, Gunderson, LL (2002) Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol 12: pp. 187-95 3/srao.2002.30827" target="_blank" title="It opens in new window">CrossRef
  34. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8:1鈥?1. / The best characterization of patterns of failure after surgery alone comes from the University of Minnesota, where 109 gastric cancer patients underwent planned re-operations as part of a therapeutic regimen.
  35. Enzinger, PC, Benedetti, JK, Meyerhardt, JA (2007) Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg 245: pp. 426-34 35088.42" target="_blank" title="It opens in new window">CrossRef
  36. Coburn, NG, Swallow, CJ, Kiss, A, Law, C (2006) Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 107: pp. 2143-51 CrossRef
  37. Ohri N, Garg MK, Aparo S, et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330鈥?. / This meta-analysis compares adjuvant chemotherapy to CRT and demonstrates an improvement in local-regional control and disease-free survival, but not overall survival, associated with CRT.聽
  38. Shridhar R, Dombi GW, Weber J, et al. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol. 2012;35:216鈥?1. / A SEER analysis of 11,630 gastric cancer patients who underwent surgery between 1990-2003 found that RT improved survival in all patients with positive lymph nodes, with a 5-year overall survival of 30 % with adjuvant RT versus 21 % without RT (p<0.0001).
  39. Fuchs CS, Tepper JE, Niedzwiecki D et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011; 29.
  40. Ajani, JA, Mansfield, PF, Janjan, N (2004) Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22: pp. 2774-80 CrossRef
  41. Ajani, JA, Winter, K, Okawara, GS (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24: pp. 3953-8 CrossRef
  42. Kim, TH, Park, SR, Ryu, KW (2012) Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 84: pp. e585-92 378" target="_blank" title="It opens in new window">CrossRef
  43. Kwon, HC, Kim, MC, Kim, KH (2010) Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol 6: pp. 278-85 3-7563.2010.01331.x" target="_blank" title="It opens in new window">CrossRef
  44. Zhu, WG, Xua, DF, Pu, J (2012) A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 104: pp. 361-6 CrossRef
  45. Huang, YY, Yang, Q, Zhou, SW (2013) Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis. PLoS ONE 8: pp. e68939 371/journal.pone.0068939" target="_blank" title="It opens in new window">CrossRef
  46. Bang, YJ, Cutsem, E, Feyereislova, A (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: pp. 687-97 36(10)61121-X" target="_blank" title="It opens in new window">CrossRef
  
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1534-6269

文摘

Gastric cancer is one of the most prevalent and deadliest forms of cancer worldwide. Even though neoadjuvant, perioperative, and adjuvant chemotherapy and/or radiation therapy may improve outcomes compared with surgery alone, the optimal combination of treatment modalities remains controversial. While European and North American trials established perioperative chemotherapy and adjuvant chemoradiation regimens for gastric cancer, Asian countries have focused on the use of adjuvant chemotherapy. This review summarizes results from contemporary randomized controlled trials and meta-analyses to elucidate the relative merits of each treatment approach.